证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20241201 | --- | --- | --- | |--------------|---------------------------------------------|--------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2024 年 12 月 23 日 | | | 地点 | 宝莱特公司会议室 | | | 参与单位名称 | 西部证券 孙阿敏、吕晔 | | | 上市公司接待 | 董事会秘书兼副总裁 | 杨永兴 | | 人员姓名 | 证券事务代表 李韵妮 证券事务专员 钟欣昊 | | | | 公司介绍环节： | | | | 宝莱特成立于 1993 | 年，主营业务为医疗器械产品的研发、生产、销 | | | | 售，主要 ...

财联社11月28日电，宝莱特公告称，其控股子公司苏州君康近日收到政府补助资金6043万元，其中与资 产相关部分占上市公司最近一期经审计净资产的3.13%，与收益相关部分占上市公司最近一期经审计净 利润绝对值的29.67%。 苏州君康获得的补助为与资产相关及与收益相关的政府补助，确认为"递延收益"，对公司本年度经营业 绩产生正面影响。 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20241101 | --- | --- | --- | |--------------|--------------------------------------------------------|--------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2024 年 11 月 19 日 | | | 地点 | 宝莱特公司会议室、腾讯会议 | | | 参与单位名称 | 现场参加公司 2024 | 年第一次临时股东大会的投资者 | | 上市公司接待 | 董事长兼总裁 燕金元 | | | 人员姓名 | 董事 | 梁瑾、黎晓明、廖伟、唐文普、陈坚 | | | 独立董事 监事 张道国、陈波、陈达元 财务总监 许薇 | 薛俊东、杨振新、冉 ...

Financial Performance - Revenue for the third quarter was RMB 271.03 million, a decrease of 5.40% year-over-year[2] - Net profit attributable to shareholders was RMB -11.13 million, a decrease of 305.27% year-over-year[2] - Operating profit dropped by 105.71% to RMB -4,802,219.77 due to decreased revenue[7] - Net profit attributable to parent company owners fell by 121.22% to RMB -13,640,452.35 due to reduced revenue[7] - Earnings per share decreased by 117.35% to RMB -0.0519 due to lower net profit[7] - Net profit attributable to parent company shareholders was -13.64 million yuan, compared to 64.28 million yuan in the previous period[17] - Basic earnings per share were -0.0519, compared to 0.2992 in the previous period[17] - Total comprehensive income was -11.32 million yuan, compared to 69.81 million yuan in the previous period[17] Cash Flow - Operating cash flow for the period was RMB -39.53 million, a decrease of 178.20% year-over-year[2] - Net cash flow from operating activities decreased by 178.20% to RMB -39,525,496.61 due to reduced sales revenue[7] - Net cash flow from operating activities was -39.53 million yuan, compared to 50.55 million yuan in the same period last year[19] - Net cash flow from investing activities was -34.98 million yuan, compared to -135.40 million yuan in the same period last year[19] - Net cash flow from financing activities was 33.13 million yuan, compared to 137.71 million yuan in the same period last year[20] - Total cash inflow from operating activities was 900.81 million yuan, compared to 1,095.18 million yuan in the same period last year[19] - Total cash outflow from operating activities was 940.34 million yuan, compared to 1,044.63 million yuan in the same period last year[19] - Cash received from tax refunds was 24.53 million yuan, compared to 34.15 million yuan in the same period last year[19] - Cash received from other operating activities was 37.80 million yuan, compared to 60.58 million yuan in the same period last year[19] - Cash paid for goods and services was 641.16 million yuan, compared to 708.42 million yuan in the same period last year[19] - Cash paid to employees was 156.15 million yuan, compared to 155.71 million yuan in the same period last year[19] - Cash paid for taxes was 34.91 million yuan, compared to 49.81 million yuan in the same period last year[19] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2.50 billion, a decrease of 1.45% compared to the end of the previous year[2] - Fixed assets increased by RMB 195.38 million, a 39.57% increase due to the transfer of construction in progress to fixed assets[6] - Construction in progress decreased by RMB 160.29 million, a 43.83% decrease due to the transfer to fixed assets[6] - Long-term loans increased by RMB 104.93 million, a 118.78% increase due to additional bank borrowings by subsidiaries[6] - Prepaid expenses increased by RMB 12.91 million, a 35.93% increase due to advance payments for sales preparation[6] - Inventory repurchase amounted to RMB 20.00 million, a 100.00% increase due to the repurchase of outstanding shares[6] - Total assets decreased from 2,534,398,019.03 yuan to 2,497,594,186.62 yuan, a decrease of 1.45%[13][14] - Total liabilities remained stable at 1,145,638,572.97 yuan compared to 1,145,452,995.95 yuan[14] - Owner's equity decreased from 1,388,945,023.08 yuan to 1,351,955,613.65 yuan, a decrease of 2.66%[14] - Monetary funds decreased from 498,717,141.39 yuan to 446,568,174.71 yuan, a decrease of 10.46%[13] - Accounts receivable increased from 247,822,625.63 yuan to 253,408,433.01 yuan, an increase of 2.25%[13] - Inventory increased from 220,374,837.03 yuan to 227,389,192.30 yuan, an increase of 3.18%[13] - Fixed assets increased from 493,750,481.02 yuan to 689,128,567.20 yuan, an increase of 39.57%[13] - Short-term borrowings decreased from 220,406,273.83 yuan to 199,804,866.68 yuan, a decrease of 9.35%[13] - Long-term borrowings increased from 88,340,000.00 yuan to 193,270,000.00 yuan, an increase of 118.78%[14] Expenses and Income - Financial expenses increased by 2754.63% to RMB 10,531,664.71 due to higher loan interest payments and exchange losses[7] - Other income decreased by 32.91% to RMB 22,898,059.80 due to reduced government subsidies and software tax refunds[7] - Total operating costs decreased to 836.47 million yuan from 902.22 million yuan, a reduction of 7.3%[16] - Sales expenses increased to 126.90 million yuan from 100.33 million yuan, a rise of 26.5%[16] - R&D expenses decreased to 56.48 million yuan from 60.76 million yuan, a reduction of 7.0%[16] - Interest income increased to 11.16 million yuan from 8.63 million yuan, a rise of 29.3%[16] - Other comprehensive income after tax was -78,553.33 yuan, compared to 980,568.80 yuan in the previous period[17] Shareholders and Equity - The total number of ordinary shareholders at the end of the reporting period is 20,002[9] - Yan Jinyuan, the largest shareholder, holds 26.72% of the shares, totaling 70,705,185 shares[9] - Wang Shi, the second-largest shareholder, holds 2.46% of the shares, totaling 6,497,280 shares, with 3,500,000 shares pledged[9] - Shenzhen Qianhai Jiuyin Investment Fund Management Co., Ltd. holds 1.46% of the shares, totaling 3,852,887 shares[9] - Yang Hedan holds 0.92% of the shares, totaling 2,439,702 shares[9] - The company's repurchase special securities account holds 2,968,800 shares, accounting for 1.12% of the total shares, ranking 4th among the top 10 shareholders[10] Legal and Operational Updates - The company has reached a comprehensive settlement with Shenzhen Mindray Bio-Medical Electronics Co., Ltd. regarding patent infringement disputes[11] - The company's subsidiary, Sanyuan Fusheng, has received approval to resume production and sales of medical devices, including hemodialysis concentrate[11] Revenue and Sales - Total operating income decreased from 951,720,699.05 yuan to 807,507,985.27 yuan, a decrease of 15.16%[15] - Cash received from sales of goods and services decreased to 838.48 million yuan from 1.00 billion yuan, a reduction of 16.2%[18] Government Subsidies - Government subsidies received during the period amounted to RMB 4.88 million[4]

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20240902 | --- | --- | --- | |--------------|--------------------------------------|-----------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2024 年 9 月 12 日 | | | 地点 | 全景网、宝莱特公司会议室 | | | 参与单位名称 | 参与 "2024 | 广东辖区上市公司投资者关系管理月活动投资者集体接待日 " 的广大投资者、申万宏源证券：黄书敏、李运斌。 | | 上市公司接待 | 董事长兼总裁 燕金元 | | | 人员姓名 | 董事会秘书兼副总裁 | 杨永兴 | | ...

证券代码：300246 证券简称：宝莱特 公告编号：2024-074 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于参加广东辖区 2024 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广东宝莱特医用科技股份有限公司（以 下简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"坚定信 心 携手共进 助力上市公司提升投资价值——2024 广东辖区上市公司投资者关 系管理月活动投资者集体接待日"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2024 年 9 月 12 日（周四） 15:30-16:30。 届时公司董事长兼总裁燕金元、董事会秘书兼副总裁杨永兴、财务总监许薇、 独立董事薛俊东（如遇特殊情况，参会人员可能进行调整）将在线就经营状况、 公司治理、发展战略等投资者关心的问题，与投资者进行沟通与交流，欢迎广大 投资者踊跃参与！ 特此公告。 广东宝 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20240901 | --- | --- | --- | |--------------|------------------------------------------------------------------|--------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 时间 | 2024 年 9 月 4 日、 | 2024 年 9 月 6 日 | | 地点 | 宝莱特公司会议室、腾讯会议 | | | 参与单位名称 | 惠州市创新投资有限公司：齐明俊 中国银河证券：刘龙刚、赵悦 | 惠州大亚湾创新投资管理有限公司：黄翀、高顺珍、黄高翔 | | | | | | 上市公司接待 | | | | 人员姓名 | 董事会秘书兼副总裁 证券事务代 ...

广东宝莱特医用科技股份有限公司 2024 年半年度报告全文 广东宝莱特医用科技股份有限公司 2024 年半年度报告 2024-071 2024 年 8 月 29 日 1 广东宝莱特医用科技股份有限公司 2024 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人燕金元、主管会计工作负责人许薇及会计机构负责人(会计主 管人员)胡淑吟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 | --- | |-------------------------------------------------------------------| | | | 本公司请投资者阅读本报告全文，并特别注意公司在本报告中详细阐述了 | | 未来可能发生的有关风险因素及对策，详见"第三节 管理层讨论与分析"之 | | "十、公司面临的风险和应对措施"。敬请广大投资者注意投资风险。 | | 公司计划不派发现金红利，不送红股， ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20240701  特定对象调研 分析师会议 投资者关系活 媒体采访 业绩说明会 动类别 新闻发布会 路演活动 现场参观 其他 时间 2024年7 月9日 地点 宝莱特公司会议室 参与单位名称 国融证券：夏桂华 远希私募：王培 和城资产：颜昌平 上市公司接待 董事会秘书兼副总裁 杨永兴先生 人员姓名 证券事务代表 李韵妮女士 证券事务专员 钟欣昊先生 公司介绍环节： ...

广东宝莱特医用科技股份有限公司2023年年度报告全文 广东宝莱特医用科技股份有限公司 2023 年年度报告 2024-029 ...